You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Anti-Insulin Receptor (phospho Y972) antibody (ab5678)

CodeSizePriceAbpointsAvailability
    
 
  • -

  •   
  •   
  •   
  •  

  •  
  •  
  •  

  •  
Updating...

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »

Overview

Product name

Anti-Insulin Receptor (phospho Y972) antibody
See all Insulin Receptor products (16) ...

Description

Rabbit polyclonal to Insulin Receptor (phospho Y972)

Specificity

In some cell systems ab5678 has been shown to cross-react with IGF1R pY950 (75% homologous).

Tested applications

IP, WBmore details

Cross reactivity

Reacts with

Mouse, Rat, Human

Immunogen

Synthetic peptide (Human). Synthetic phosphopeptide derived from the region of the human Insulin Receptor that contains tyrosine 972 (as numbered according to Ebina, et al. (tyrosine 960 according to Ullrich, et al.).

Positive control

CHO-T cells transfected with a vector encoding the human insulin receptor and stimulated with insulin, and 3T3-L1 adipocytes +/- insulin stimulation.

Properties

Form

Liquid

Storage instructions

Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Storage buffer

Preservative: 0.05% Sodium Azide
Constituents: 0.1% BSA, PBS, pH 7.4

Concentration

Concentration information loading...

Purity

Immunogen affinity purified

Purification notes

The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated Insulin Receptor (IR). The final product is generated by affinity chromatography using an IR-derived peptide phosphorylated at tyrosine 972.

Primary antibody notes

Biological actions of insulin are mediated by the Insulin Receptor (IR), a receptor tyrosine kinase that regulates multiple signaling pathways through activation of a series of phosphorylation cascades. The IR is a heterotetrameric protein consisting of two ligand-binding alpha subunits and two beta subunits that each contain a tyrosine kinase domain. Insulin binding to the extracellular domain leads to autophosphorylation of the receptor and activation of the intrinsic tyrosine kinase activity, which allows appropriate substrates to be phosphorylated. Tyrosine 972 is in the juxtamembrane Asn-Pro- Glu-Tyr (NPEY) motif. Phosphorylation of IR tyrosine 972 is required for the binding and/or phosphorylation of the adapter protein Shc, the PTB domain, IRS-1, PI3 kinase, and the Suppressor of Cytokine Signaling (SOCS).

Clonality

Polyclonal

Isotype

IgG

  • Western blot - Anti-Insulin Receptor (phospho Y972) antibody (ab5678)Western blot - Anti-Insulin Receptor (phospho Y972) antibody (ab5678) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab5678 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • ShowHide

    IP

     IP: Use at an assay depe...Read more →

    IP: Use at an assay dependent dilution. PubMed: 17264162

  • ShowHide1 Image

    WB

     WB: Use a concentration ...Read more →

    WB: Use a concentration of 0.1 - 1 µg/ml. Detects a band of approximately 110 kDa.

Target

Function

Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.

Tissue specificity

Isoform Long and isoform Short are predominantly expressed in tissue targets of insulin metabolic effects: liver, adipose tissue and skeletal muscle but are also expressed in the peripheral nerve, kidney, pulmonary alveoli, pancreatic acini, placenta vascular endothelium, fibroblasts, monocytes, granulocytes, erythrocytes and skin. Isoform Short is preferentially expressed in fetal cells such as fetal fibroblasts, muscle, liver and kidney. Found as a hybrid receptor with IGF1R in muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at protein level). Overexpressed in several tumors, including breast, colon, lung, ovary, and thyroid carcinomas.

Involvement in disease

Defects in INSR are the cause of Rabson-Mendenhall syndrome (RMS) [MIM:262190]; also known as Mendenhall syndrome. RMS is a severe insulin resistance syndrome characterized by insulin-resistant diabetes mellitus with pineal hyperplasia and somatic abnormalities. Typical features include coarse, senile-appearing facies, dental and skin abnormalities, abdominal distension, and phallic enlargement. Inheritance is autosomal recessive.
Defects in INSR are the cause of leprechaunism (LEPRCH) [MIM:246200]; also known as Donohue syndrome. Leprechaunism represents the most severe form of insulin resistance syndrome, characterized by intrauterine and postnatal growth retardation and death in early infancy. Inheritance is autosomal recessive.
Defects in INSR may be associated with noninsulin-dependent diabetes mellitus (NIDDM) [MIM:125853]; also known as diabetes mellitus type 2.
Defects in INSR are the cause of familial hyperinsulinemic hypoglycemia type 5 (HHF5) [MIM:609968]. Familial hyperinsulinemic hypoglycemia [MIM:256450], also referred to as congenital hyperinsulinism, nesidioblastosis, or persistent hyperinsulinemic hypoglycemia of infancy (PPHI), is the most common cause of persistent hypoglycemia in infancy and is due to defective negative feedback regulation of insulin secretion by low glucose levels.
Defects in INSR are the cause of insulin-resistant diabetes mellitus with acanthosis nigricans type A (IRAN type A) [MIM:610549]. This syndrome is characterized by the association of severe insulin resistance (manifested by marked hyperinsulinemia and a failure to respond to exogenous insulin) with the skin lesion acanthosis nigricans and ovarian hyperandrogenism in adolescent female subjects. Women frequently present with hirsutism, acne, amenorrhea or oligomenorrhea, and virilization. This syndrome is different from the type B that has been demonstrated to be secondary to the presence of circulating autoantibodies against the insulin receptor.

Sequence similarities

Belongs to the protein kinase superfamily. Tyr protein kinase family. Insulin receptor subfamily.
Contains 3 fibronectin type-III domains.
Contains 1 protein kinase domain.

Post-translational
modifications

After being transported from the endoplasmic reticulum to the Golgi apparatus, the single glycosylated precursor is further glycosylated and then cleaved, followed by its transport to the plasma membrane.
Autophosphorylated on tyrosine residues in response to insulin. Phosphorylation of Tyr-999 is required for IRS1-, SHC1-, and STAT5B-binding. Dephosphorylated by PTPRE on Tyr-999, Tyr-1185, Tyr-1189 and Tyr-1190 residues. Dephosphorylated by PTPRF.

Cellular localization

Membrane.

Target information above from: UniProt accessionP06213 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • CD 220 antibody
  • CD220 antibody
  • CD220 antigen antibody
  • HHF 5 antibody
  • HHF5 antibody
  • human insulin receptor antibody
  • INSR antibody
  • INSR_HUMAN antibody
  • Insulin receptor subunit beta antibody
  • IR antibody
  • IR-1 antibody
see all

Anti-Insulin Receptor (phospho Y972) antibody images:

  Western blot - Anti-Insulin Receptor (phospho Y972) antibody (ab5678)

Western blot - Anti-Insulin Receptor (phospho Y972) antibody (ab5678)

Peptide Competition: Extracts prepared from CHO-T cells stimulated with insulin were resolved by SDS-PAGE on a 10% Tris-glycine gel, and transferred to PVDF. Membranes were incubated with 0.50µg/mL ab5678 antibody, following prior incubation in the presence of: the phosphopeptide immunogen (1), the non-phosphopeptide corresponding to the Insulin Receptor phosphopeptide (2), a generic phosphotyrosine containing peptide (3), or, the absence of the phosphopeptide immunogen (4). After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and bands were detected using the Tropix WesternStar detection method. The data show detection of a single band corresponding to the â-subunit (~95 kDa) of the Insulin Receptor. The data also show that only the phosphopeptide corresponding to this site blocks the antibody signal, demonstrating the specificity of the ab5678 antibody for this epitope. Insulin Stimulation Extracts prepared from CHO-T cells without (-) and with (+) insulin stimulation were resolved by SDS-PAGE on a 10% Tris-glycine gel, transferred to PVDF, and incubated with 0.50 µg/mL ab5678 antibody. After washing, membranes were incubated with goat F(ab’)2 anti-rabbit IgG alkaline phosphatase and bands were detected using the Tropix WesternStar detection method. The data show induction of the pY972 epitope in response to stimulation with insulin.

References for Anti-Insulin Receptor (phospho Y972) antibody (ab5678)

This product has been referenced in:

  • Uhles S  et al. Selective gene activation by spatial segregation of insulin receptor B signaling. FASEB J 21:1609-21 (2007). WB, IP; Rat.Read more (PubMed: 17264162) »

See 1 publication for this product

Publishing research using ab5678? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"